The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey.

Uzunkopru, Cihat; Tutuncu, Melih; GÜNDÜZ, Tuncay; Gumus, Haluk; Sen, Sedat; Demir, Serkan; Cinar, Bilge; Ture, Hatice; Uygunoglu, Ugur; Togrol, Rifat; Terzi, Murat; Kurtuncu, Murat; Ozakbas, Serkan; Tutuncu, MELİH; Beckmann, Yesim; Siva, AKSEL

doi:10.1111/ijcp.14158

The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey.

Uzunkopru C., Tutuncu M., GÜNDÜZ T., Gumus H., Sen S., Demir S., ...Daha Fazla

International journal of clinical practice, cilt.75, sa.7, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 75 Sayı: 7
Basım Tarihi: 2021
Doi Numarası: 10.1111/ijcp.14158
Dergi Adı: International journal of clinical practice
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background Neuromyelitis optica spectrum disorders (NMOSD) are a group of antibody-mediated chronic inflammatory diseases of the central nervous system. Rituximab is a monoclonal antibody that leads to a reduction in disease activity.